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Local setting Mexico's public expenditure on pharmaceuticals has increased substantially in the past decade owing to government efforts to achieve universal health-care coverage through Seguro Popular, an insurance programme introduced in 2004 that guarantees access to a comprehensive package of health services and medicines.
Relevant changes Since 2008, the CCPNM has improved procurement practices in Mexico's public health institutions and has achieved significant price reductions resulting in substantial savings in public pharmaceutical expenditure.
Lessons learnt
The CCPNM has successfully changed the landscape of price negotiation for patented medicines in Mexico. However, it is also facing challenges, including a lack of explicit indicators to assess CCPNM performance; a shortage of permanent staff with sufficient technical expertise; poor coordination among institutions in preparing background materials for the annual negotiation process in a timely manner; insufficient communication among committees and institutions, and a lack of political support to ensure the sustainability of the CCPNM.
Background
As low-and middle-income countries seek to expand health insurance coverage, they are faced with an increase in medicine consumption and with the need to mobilize financial resources to pay for rising pharmaceutical expenditure. In Mexico, public expenditure on pharmaceuticals has increased substantially owing to government efforts to attain universal health-care coverage through Seguro Popular, a new insurance programme that guarantees its affiliates access to a comprehensive package of health services and medicines. 5, 6 The programme aimed to cover the fraction of the population previously uninsured, which was 50%. According to the government, this target coverage was achieved in 2012. 7 In Mexico's public sector, all public institutions must tender for pharmaceutical products obtainable from multiple sources, such as generic medicines. For products available only from a single source, including patented medicines, the law allows direct purchase and price negotiation with pharmaceutical firms. 8 However, a recent analysis of the public procurement prices for patented products unveiled price variations as high as 3000% among public institutions, which suggests large inefficiencies and flaws in the public procurement process. 9 In Mexico, only 4% of all medicines approved for marketing are patented. However, these patented products represent 56% of the total public expenditure on pharmaceuticals (around 1.3 billion United States dollars [US$] at the mean exchange rate for January 2012, 13.7
Mexican pesos per US dollar). 10, 11 Publication The present study assesses the operation and performance of the CCPNM to extract lessons for Mexico and other countries that are also attempting to contain pharmaceutical expenditure while expanding health-care coverage. We performed an analysis of the annual reports of the CCPNM provided by the Ministry of Health and conducted 10 formal interviews with key informants, after obtaining their consent, to determine the structure and organization of the CCPNM, its objectives and its performance indicators. The key informants included members of the CCPNM or of its technical advisory committees, advisers to the president of the CCPNM and policy analysts.
Operation of the CCPNM
The CCPNM was created through a presidential decree signed on 26 February 2008 and is headed by a presidential appointee whose term lasts for two years. The annual reports of the CCPNM showed that, for most patented medicines, every year the negotiations resulted in large price reductions with reference to the preceding year.
According to the reports, the accumulated direct savings (e.g. price reductions resulting from the negotiation) over 2008-2011 reached a total of US$ 355 million (Table 1) .
Evaluation and lessons learnt
Overall, the actions taken by the Mexican Government to address rising pharmaceutical expenditures in the public sector are marked by some successes but also several challenges (Box Two other issues should be addressed in the future. First, the CCPNM needs to develop better methods for assessing its impact on prices and the savings produced. This assessment could weigh the costs of establishing and operating the CCPNM against the net benefits achieved through lower prices. Second, the work of the CCPNM needs to be made more transparent, since annual reports are circulated only within the three public health institutions belonging to the CCPNM and the subnational health ministries of the 31 states and federal district. Increased transparency and accountability to other stakeholders (e.g. civil society and academic institutions) could enhance trust and garner support for the work of the CCPNM, since procurement is an area perceived as easily harbouring corruption. 4 In conclusion, the creation of the CCPNM has changed the landscape of the price negotiation process for patented medicines in Mexico and has improved procurement practices within public health institutions. However, Mexico needs to address several continuing challenges to make the procurement of expensive medicines in the public sector more efficient.
Mexico's experiences with its new government entity charged with facilitating the public
Box 1. Summary of main lessons learnt
• Coordination among public institutions in negotiating the public procurement price of patented drugs can result in large price reductions.
• Well-defined, explicit performance indicators are necessary to rigorously evaluate the impact of Mexico's CCPNM on the procurement price of patented medicines.
• Political support is needed to ensure the timely preparation of the negotiations, the availability of human resources able to conduct complex negotiations and adequate continued functioning of the CCPNM.
CCPNM, Coordinating Commission for Negotiating the Price of Medicines and other Health Inputs. 
